AR031726A1 - Nuevos compuestos de aminotriazolona, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden - Google Patents
Nuevos compuestos de aminotriazolona, un procedimiento para su preparacion y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR031726A1 AR031726A1 ARP010104790A ARP010104790A AR031726A1 AR 031726 A1 AR031726 A1 AR 031726A1 AR P010104790 A ARP010104790 A AR P010104790A AR P010104790 A ARP010104790 A AR P010104790A AR 031726 A1 AR031726 A1 AR 031726A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- straight
- branched
- unsubstituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000004432 carbon atom Chemical group C* 0.000 abstract 9
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 229910052757 nitrogen Chemical group 0.000 abstract 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 229910052717 sulfur Inorganic materials 0.000 abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 239000001301 oxygen Substances 0.000 abstract 4
- 239000011593 sulfur Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 125000004122 cyclic group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005549 heteroarylene group Chemical group 0.000 abstract 3
- 150000002825 nitriles Chemical class 0.000 abstract 3
- -1 nitro, amino Chemical group 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- 230000007170 pathology Effects 0.000 abstract 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004450 alkenylene group Chemical group 0.000 abstract 2
- 125000004419 alkynylene group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 abstract 2
- 125000004957 naphthylene group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- CNQPUJGRCGXCKT-UHFFFAOYSA-N 5-aminotriazol-4-one Chemical class NC1=NN=NC1=O CNQPUJGRCGXCKT-UHFFFAOYSA-N 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 102000003797 Neuropeptides Human genes 0.000 abstract 1
- 108090000189 Neuropeptides Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037849 arterial hypertension Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 239000004305 biphenyl Chemical group 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 125000005046 dihydronaphthyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 230000032258 transport Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos de aminotriazolona de formula (1), donde R1 y R2 cada uno independientemente de los otros, representan un átomo de hidrogeno o un grupo alquilo sustituido o insustituido, un grupo alquenilo sustituido o insustituido, un grupo alquinilo sustituido o insustituido, un grupo arilo sustituido o insustituido, un grupo heteroarilo sustituido o insustituido, un grupo cicloalquilo sustituido o insustituido, o un grupo heterocicloalquilo sustituido o insustituido, entendiéndose que al menos uno de los grupos R1 y R2 es diferente de un átomo de hidrogeno, R3 representa un átomo de hidrogeno o un grupo alquilo sustituido o insustituido, un grupo alquenilo sustituido o insustituido, un grupo alquinilo sustituido o insustituido, un grupo arilo sustituido o insustituido, un grupo heteroarilo sustituido o insustituido o un grupo heterocicloalquilo sustituido o insustituido, R4 representa un grupo de formula (2), donde W representa un enlace o una cadena de alquileno que contiene de 1 y 6 átomos de carbono, y B representa un grupo mono- o poli-cíclico, aromático o no aromático, que contiene anillos de entre 3 y 10 átomos, que puede incluir, de resultar conveniente, entre 1 y 3 heteroátomos seleccionados entre oxígeno, azufre y nitrogeno, y que contiene uno o más sustituyentes seleccionados entre oxo, -COR (donde R representa un átomo de hidrogeno o un grupo alquilo, alcoxi, amino, alquilamino o dialquilamino) y un sustituyente de hidroxi, y que puede contener, de resultar conveniente, una o más insaturaciones y/o uno o más sustituyentes (además del grupo oxo, COR o hidroxi de acuerdo con lo definido con anterioridad) seleccionados entre alquilo, alcoxi, arilo, arilalquilo y átomos de halogeno, R5 representa un átomo de hidrogeno o un grupo alquilo, A representa un grupo seleccionado entre -A2-, -A1-A2-, -A2-A1- y -A1-A2-A1-, donde A1 es un grupo alquileno, alquenileno o alquinileno y A2 representa un grupo fenileno sustituido o insustituido, un grupo naftileno sustituido o insustituido, un grupo cicloalquileno sustituido o insustituido, un grupo heteroarileno sustituido o insustituido, o un grupo heterocicloalquileno sustituido o insustituido; - V representa un enlace o un grupo -CH2-, -CO-, -CS-, -CH2-NH- o -CH=N, o V y R3, junto con los grupos -A- y -N-R4 que los transporta, forman un grupo -A-CH=N-R4, entendiéndose que; - el término "alquilo" hace referencia a un grupo recto o ramificado que tiene entre 1 y 6 átomos de carbono; - el término "alquileno" hace referencia a un radical bivalente recto o ramificado que contiene entre 1 y 6 átomos de carbono; - el término "alquenilo" hace referencia a un grupo recto o ramificado que contiene entre 2 y 6 átomos de carbono y entre 1 y 3 enlaces dobles; - el término "alquenileno" hace referencia a un radical bivalente recto o ramificado que contiene entre 2 y 6 átomos de carbono y entre 1 y 3 enlaces dobles; - el término "alquinilo" hace referencia a un grupo recto o ramificado que contiene entre 2 y 6 átomos de carbono y entre 1 y 3 enlaces triples; - el término "alquinileno" hace referencia a un radical bivalente recto o ramificado que contiene entre 2 y 6 átomos de carbono y entre 1 y 3 enlaces triples; - el término "arilo" hace referencia a un grupo fenilo, naftilo, bifenilo, dihidronaftilo o tetrahidro-naftilo; - el término "heteroarilo" hace referencia a un grupo mono- o bi-cíclico insaturado o parcialmente insaturado que tiene anillos entre 5 y 11 miembros, que contiene entre 1 y 4 heteroátomos sleccionados entre nitrogeno, oxígeno y azufre; - los términos "fenileno" y naftileno" hacen referencia a radicales de fenilo y naftilo bivalentes, respectivamente; - el término "heteroarileno" hace referencia a un radical de heteroarilo bivalente, siendo el heteroarilo el definido con anterioridad en la presente; - el término "heterocicloalquilo" hace referencia a un grupo mono- o bi-cíclico saturado que tiene anillos de entre 4 y 11 miembros, que contiene entre 1 y 4 heteroátomos seleccionados entre nitrogeno, oxígeno y azufre; - el término "heterocicloalquileno" hace referencia a un radical bivalente mono- o bi-cíclico saturado que tiene anillos de entre 4 y 11 miembros, que contiene entre 1 y 4 heteroátomos seleccionados entre nitrogeno, oxígeno y azufre; - el término "cicloalquilo" hace referencia a un grupo cíclico saturado que contiene entre 3 y 8 átomos de carbono; - el término " cicloalquileno" hace referencia a un grupo cíclico bivalente saturado que contiene entre 3 y 8 átomos de carbono; la expresion "sustituido" aplicada a los términos "arilo" o "heteroarilo" significa que aquellos grupos son sustituidos en su parte cíclica por entre 1 y 5 sustituyentes idénticos o diferentes seleccionados entre (C1-6)alquilo recto o ramificado, (C1-6)alcoxi recto o ramificado, halogeno, hidroxi, (C1-6)-perhaloalquilo recto o ramificado, nitro, amino (insustituido o sustituido por uno o dos grupos sleccionados entre (C1-6)alquilo, arilo y heteroarilo rectos o ramificados), (C1-6)acilo recto o ramificado, aminocarbonilo (opcionalmente sustituido en el átomo de nitrogeno por uno o dos grupos (C1-6)alquilo recto o ramificado), (C1-6)acilamino recto o ramificado, (C1-6)alcoxi-carbonilo recto o ramificado, formilo, carboxi, sulfo, sulfino, sulfamoilo, nitrilo, (C1-6)aminoalquilo recto o ramificado (opcionalmente sustituido en el átomo de nitrogeno por uno o dos grupos (C1-6)alquilo recto o ramificado) (C1-6)tioalquilo recto o ramificado (opcionalmente sustituido en el átomo de azufre por un grupo (C1-6)alquilo recto o ramificado) e hidroxialquilo (opcionalmente sustituido en el átomo de oxígeno por un grupo (C1-6)alquilo recto o ramificado); - la expresion "sustituido" aplicada a los términos"alquilo, "alquenilo" o "alquinilo" significa que aquellos grupos pueden ser sustituidos por uno o más grupos seleccionados entre hidroxi, cicloalquilo sustituido o insustituido, arilo sustituido o insustituido, heteroarilo sustituido o insustituido, heterocicloalquilo sustituido o insustituido y átomos de halogeno; la expresion "sustituido" aplicada a los términos "fenileno", "naftileno" o " heteroarileno" significa que aquellos grupos son sustituidos por entre 1 y 3 grupos idénticos o diferentes seleccionados entre (C1-6)alquilo recto o ramificado, (C1-6)alcoxi recto o ramificado, halogeno, hidroxi (C1-6)-perhaloalquilo recto o ramificado, nitro, amino (insustituido o sustituido) por 1 o 2 grupos seleccionados entre arilo, heteroarilo y (C1-6)alquilo rectos o ramificados), (C1-6)acilo recto o ramificado, formilo, carboxi, (C1-6)alcoxi-carbonilo recto o ramificado, aminocarbonilo (opcionalmente sustituido en el átomo de nitrogeno por uno o dos grupos (C1-6)alquilo recto o ramificado), (C1-6)acilamino recto o ramificado y nitrilo, sus enantiomeros, diastereoisomeros, y sales de adicion de los mismos con una base o un ácido farmacéuticamente aceptable. Estos compuestos son utilizados para el tratamiento de patologías asociadas con el neruopéptido y (NPY) estos han demostrado una accion inhibitoria in vivo en la ingesta de alimentos y en el aumento de peso. Ese efecto es ejercido al unirse a los receptores de NPY. Así, es posible utilizar los compuestos de la presente en el tratamiento de patologías que requieren de un ligando de receptores de NPy, especialmetne en el tratamiento de patologías asociadas con trastornos en el comportamiento alimentario o trastornos en el equilibrio energético, como ser diabetes, obesidad, bulimia y anorexia nerviosa, y también en el tratamiento de hipertension arterial, ansiedad, depresion, epilepsia, disfunciones sexuales y trastornos del sueno. También se divulga un procedimiento para su preparacion y composiciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0013125A FR2815346B1 (fr) | 2000-10-13 | 2000-10-13 | Nouveaux composes aminotriazolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031726A1 true AR031726A1 (es) | 2003-10-01 |
Family
ID=8855314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010104790A AR031726A1 (es) | 2000-10-13 | 2001-10-12 | Nuevos compuestos de aminotriazolona, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040029875A1 (es) |
| EP (1) | EP1324998A1 (es) |
| JP (1) | JP2004515475A (es) |
| KR (1) | KR20030036929A (es) |
| CN (1) | CN1468233A (es) |
| AR (1) | AR031726A1 (es) |
| AU (1) | AU2002210632A1 (es) |
| BR (1) | BR0114632A (es) |
| CA (1) | CA2424802A1 (es) |
| CZ (1) | CZ20031290A3 (es) |
| EA (1) | EA200300458A1 (es) |
| FR (1) | FR2815346B1 (es) |
| HU (1) | HUP0302408A2 (es) |
| MX (1) | MXPA03002956A (es) |
| NO (1) | NO20031643D0 (es) |
| PL (1) | PL360090A1 (es) |
| SK (1) | SK5712003A3 (es) |
| WO (1) | WO2002030923A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7931696B2 (en) * | 2007-01-31 | 2011-04-26 | BASF SE Ludwigshafen | Cationic dyes |
| JP5869222B2 (ja) | 2008-01-04 | 2016-02-24 | インテリカイン， エルエルシー | 特定の化学的実体、組成物および方法 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| KR100971811B1 (ko) * | 2008-03-27 | 2010-07-22 | 엘에스전선 주식회사 | 커넥터가 구비된 광복합 전력케이블 접속함 |
| MX347708B (es) | 2011-01-10 | 2017-05-09 | Infinity Pharmaceuticals Inc | Proceso para preparar isoquinolinonas y formas solidas de isoquinolinonas. |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| WO2014122150A1 (en) * | 2013-02-05 | 2014-08-14 | Basf Se | Process for preparing a boron containing zeolitic material having mww framework structure |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| MX391135B (es) | 2016-06-24 | 2025-03-21 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2435521C3 (de) * | 1974-07-24 | 1982-01-21 | L. & C. Steinmüller GmbH, 5270 Gummersbach | Selbsttragendes Beton-Stahl-Verbundelement zur Auskleidung von Behältern |
| PT76280A (en) * | 1982-02-24 | 1983-03-01 | Glaxo Group Ltd | Process for preparing heterocyclic derivatives |
| GB2236339B (en) * | 1989-09-07 | 1994-06-01 | Kajima Corp | Trusses and precast concrete slabs reinforced thereby |
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| DE69729315T2 (de) * | 1996-12-16 | 2005-06-23 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazolderivate |
| CO5011105A1 (es) * | 1997-12-22 | 2001-02-28 | Novartis Ag | Compuestos organicos para tratar la obesidad y desordenes relacionados, composiciones farmaceuticas que los comprenden y procesos para su preparacion |
-
2000
- 2000-10-13 FR FR0013125A patent/FR2815346B1/fr not_active Expired - Fee Related
-
2001
- 2001-10-11 KR KR10-2003-7005208A patent/KR20030036929A/ko not_active Ceased
- 2001-10-11 CA CA002424802A patent/CA2424802A1/fr not_active Abandoned
- 2001-10-11 HU HU0302408A patent/HUP0302408A2/hu unknown
- 2001-10-11 CZ CZ20031290A patent/CZ20031290A3/cs unknown
- 2001-10-11 JP JP2002534309A patent/JP2004515475A/ja active Pending
- 2001-10-11 CN CNA018170587A patent/CN1468233A/zh active Pending
- 2001-10-11 MX MXPA03002956A patent/MXPA03002956A/es not_active Application Discontinuation
- 2001-10-11 US US10/399,098 patent/US20040029875A1/en not_active Abandoned
- 2001-10-11 WO PCT/FR2001/003133 patent/WO2002030923A1/fr not_active Ceased
- 2001-10-11 EP EP01978526A patent/EP1324998A1/fr not_active Withdrawn
- 2001-10-11 PL PL01360090A patent/PL360090A1/xx not_active Application Discontinuation
- 2001-10-11 SK SK571-2003A patent/SK5712003A3/sk unknown
- 2001-10-11 BR BR0114632-7A patent/BR0114632A/pt not_active IP Right Cessation
- 2001-10-11 AU AU2002210632A patent/AU2002210632A1/en not_active Abandoned
- 2001-10-11 EA EA200300458A patent/EA200300458A1/ru unknown
- 2001-10-12 AR ARP010104790A patent/AR031726A1/es not_active Application Discontinuation
-
2003
- 2003-04-10 NO NO20031643A patent/NO20031643D0/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2424802A1 (fr) | 2002-04-18 |
| US20040029875A1 (en) | 2004-02-12 |
| JP2004515475A (ja) | 2004-05-27 |
| NO20031643L (no) | 2003-04-10 |
| FR2815346A1 (fr) | 2002-04-19 |
| AU2002210632A1 (en) | 2002-04-22 |
| CN1468233A (zh) | 2004-01-14 |
| FR2815346B1 (fr) | 2004-02-20 |
| WO2002030923A1 (fr) | 2002-04-18 |
| EA200300458A1 (ru) | 2003-08-28 |
| EP1324998A1 (fr) | 2003-07-09 |
| HUP0302408A2 (hu) | 2003-12-29 |
| KR20030036929A (ko) | 2003-05-09 |
| NO20031643D0 (no) | 2003-04-10 |
| SK5712003A3 (en) | 2003-11-04 |
| CZ20031290A3 (cs) | 2003-08-13 |
| BR0114632A (pt) | 2004-02-17 |
| PL360090A1 (en) | 2004-09-06 |
| MXPA03002956A (es) | 2004-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580768A2 (es) | Derivados de 4,5-diariltiazol como ligandos cb-1 | |
| AR031726A1 (es) | Nuevos compuestos de aminotriazolona, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| AR006720A1 (es) | Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende | |
| CO5690638A2 (es) | Nuevos compuestos triciclicos utiles para el tratamiento de desordenes inflamatorios y alergicos; proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR043674A1 (es) | Derivados de piridazinona como inhibidores no nucleosidos de la transcriptasa reversa | |
| CO5580746A2 (es) | Derivados de fenil-piperazina como inhibidores de la reabsorcion de la serotonina | |
| ATE444279T1 (de) | Modulatoren von cannabinoidrezeptoren | |
| AR057244A1 (es) | Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes. | |
| CR8755A (es) | Derivado de quinolina fusionada y uso del mismo | |
| CY1107008T1 (el) | Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii | |
| PE20091425A1 (es) | Derivados de aminotiazol | |
| AR038883A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos | |
| RU2343145C2 (ru) | Производные изоиндолина | |
| AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| ATE16596T1 (de) | Phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel. | |
| RU2008136762A (ru) | Циклические сульфоны как ингибиторы васе | |
| CO5550494A2 (es) | Derivados de diamina, proceso para producir los derivados de diamina, y fungicidas que contienen los derivados de diamina como ingrediente activo | |
| BRPI0608216A2 (pt) | agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo | |
| ES472290A1 (es) | Un procedimiento para preparar un compuesto de benceno di- sustituido en orto | |
| ES417638A1 (es) | Procedimiento para preparar oxazoles 2,4,5-trisustituidos. | |
| AR054813A1 (es) | Derivados de pirroloquinolinas y sus usos como inhibidores de proteinas quinasas | |
| RU2007121503A (ru) | N-замещенные имиды как инициаторы полимеризации | |
| AR039560A1 (es) | Composicion pesticida para controlar parasitos en un animal, derivados de alquilaminopirazol, preparacion del compuesto y sus usos | |
| CO5660290A2 (es) | 6-(1,1-difluoroalquil)-4-aminopicolinatos y su uso como herbicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |